This pleiotropic activity of SMIs seems to be an attractive property for the area of MM immunotherapy aimed at breaking immune suppression, and appears to be of special interest, especially in view of our notion that PD-1 and CTLA-4 could be less accessible for ICIs in MM. The gene discussed is CTLA4; the disease is Miyoshi myopathy.